Table 2.
Type-specific HPV prevalence and HPV prevalence of tissue-based detection in healthy women from mainland, stratified by cervical disease grade
| HPV type | NILM | CIN1 | CIN2 | ≥CIN3 |
|---|---|---|---|---|
| HPV ration | 10.5 (8.4,12.7) | 73.9 (65.8,80.8) | 89.5 (84.3,94.4) | 91.5 (80.3,96.8) |
| HPV6/11 | 0.4 (0.2,0.6) | 3.7 (2.0,5.4) | 2.0 (0.8,3.2) | 3.5 (1.5,5.4) |
| HPV16 | 2.4 (1.8,3.1) | 25.0 (16.1,33.9) | 49.9 (28.8,70.9) | 62.0 (46.5,77.6) |
| HPV18 | 0.7 (0.5,1.0) | 7.7 (5.5,9.8) | 6.9 (2.2,11.5) | 15.8 (5.2,20.4) |
| HPV58 | 1.4 (0.9,1.8) | 13.5 (10.3,16.7) | 16.1 (9.74,22.4) | 12.3 (8.1,16.5) |
| HPV52 | 2.3 (1.1,3.6) | 19.3 (12.4,26.1) | 13.9 (6.6,21.3) | 10.2 (5.0,15.4) |
| HPV31 | 0.5 (0.3,0.8) | 4.7 (1.8,7.6) | 7.7 (2.4,13.0) | 6.4 (1.5,11.4) |
| HPV33 | 0.6 (0.4,0.8) | 17.0 (15.6,18.3) | 11.1 (6.9,15.3) | 3.7 (2.2,5.3) |
| HPV68 | 0.5 (0.3,0.6) | 5.4 (4.1,6.6) | 3.9 (2.5,5.4) | 3.6 (2.0,5.1) |
| HPV35 | 0.3 (0.1,0.5) | 3.6 (1.2,3.0) | 6.6 (3.9,9.4) | 2.1 (0.4,3.8) |
| HPV6 | 0.1 (0.1,0.2) | 2.4 (1.08,3.7) | 1.7 (0.1,3.2) | 2.1 (0.9,3.4) |
| HPV59 | 0.3 (0.2,0.4) | 2.8 (1.6,3.9) | 1.6 (0.5,2.8) | 1.8 (0.7,3.0) |
| HPV66 | 0.4 (0.27,0.7) | 4.1 (1.5,6.7) | 3.4 (1.9,4.9) | 1.7 (0.5,2.8) |
| HPV39 | 0.7 (0.4,1.0) | 4.7 (2.8,6.6) | 3.5 (2.1,4.8) | 1.3 (0.3,2.3) |
| HPV51 | 0.6 (0.3,0.9) | 4.3 (3.2,5.4) | 4.5 (2.2,6.9) | 1.6 (0.4,4.0) |
| HPV45 | 0.2 (0.1,0.4) | 1.5 (0.8,2.3) | 3.1 (1.2,4.9) | 0.8 (0.0,1.6) |
| HPV56 | 0.5 (03,0.7) | 3.1 (2.1,4.0) | 3.3 (2.0,4.7) | 0.6 (0.1,1.3) |
| HPV11 | 0.2 (0.1,0.3) | 1.8 (0.7,3.7) | 1.2 (0.2,2.2) | 0.6 (0.1,1.2) |
CIN2=cervical intraepithelial neoplasia grade 2; CIN1=cervical intraepithelial neoplasia grade 1; ≥CIN3=cervical intraepithelial neoplasia grade 3and cancer; NILM: No intraepithelial lesion or malignant cells